BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khai NC, Sakamoto K, Takamatsu H, Matsufuji H, Kosai K. Recombinant soluble form of heparin-binding epidermal growth factor-like growth factor protein therapy drastically inhibits Fas-mediated fulminant hepatic failure: Implications in clinical application. Hepatol Res 2011;41:594-6. [PMID: 21535334 DOI: 10.1111/j.1872-034X.2011.00805.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Sakamoto K, Khai NC, Wang Y, Irie R, Takamatsu H, Matsufuji H, Kosai KI. Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms. Int J Mol Med 2016;38:1673-82. [PMID: 27779646 DOI: 10.3892/ijmm.2016.2784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]